ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
39 announcements with these filters
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to 'IND AA+' and affirmed short-term ratings at 'IND A1+'.
Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in various dosages. This launch expands the company's injectable portfolio and presence in the U.S. hospital market.
Glenmark Pharmaceuticals received U.S. FDA approval for its Fluticasone Propionate Nasal Spray. The product will be distributed in the U.S. market.
Glenmark Pharmaceuticals released its Business Responsibility & Sustainability Report for the financial year 2025-26. This filing adheres to SEBI's regulatory disclosure requirements.
Glenmark Pharmaceuticals Limited has issued the notice for its 48th Annual General Meeting, scheduled to be held on September 11, 2026, through video conferencing.
Glenmark Pharmaceuticals agreed to a $15.28 million settlement with Humana, Inc. to resolve antitrust litigation. This payment has been fully provided for in the company's financials.
Glenmark Pharmaceuticals Limited has allotted 23,863 equity shares following the exercise of options under its ESOP 2016 scheme. This allotment increases the company's paid-up capital to Rs. 28,22,24,672.
Glenmark reported Q1 FY27 consolidated revenue of INR 40,185 million, a 23.1% YoY increase. Performance was driven by India growth (15.5%) and North America recovery (41.1%).
Glenmark delivered robust 23.1% revenue growth for Q1 FY27, driven by strong recovery in North America and steady India outperformance, despite persistent geopolitical cost pressures.
Glenmark reported strong Q1 FY27 results with consolidated revenue of Rs. 40,185 million, representing 23.1% YoY growth. Strategy focuses on core business strengthening and expanding innovation-led platforms like RYALTRIS®.
Glenmark Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹4,018.5 Crore, a 23.1% YoY growth, with an EBITDA of ₹804.8 Crore.
Glenmark Pharmaceuticals updated its list of key officials authorized to determine event materiality and manage stock exchange disclosures under Regulation 30(5) of SEBI LODR.
Glenmark Pharmaceuticals Ltd reported revenue from operations of ₹4,018 Cr (+23.1% YoY) and net profit of ₹482.8 Cr (+927.2% YoY) for Q1 FY27.
Glenmark Pharmaceuticals launched Sugammadex Injection in the U.S. market. This addition strengthens the company's injectable portfolio and presence in the hospital segment.
Glenmark received U.S. FDA approval to expand the use of its RYALTRIS nasal spray to pediatric patients aged 6 to less than 12 years.
Glenmark Pharmaceuticals scheduled a board meeting on July 31, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
Glenmark advanced its Phase 3 trial for Trastuzumab rezetecan in ovarian cancer. India is first to enroll, with plans for Australia and South Korea pending approvals.
Glenmark's Goa facility received a US FDA Form 483 with six procedural observations. The company expects no impact on commercial product supply.
Glenmark aims to become a US$2bn+ revenue company by FY26, shifting its portfolio mix toward >70% branded products by FY30e through global innovation in Oncology, Respiratory, and Dermatology.
Glenmark reported 15.8% Q4 revenue growth (INR 37,706 Mn) and 27.5% FY26 growth. Strategy focuses on respiratory, oncology innovations, and U.S. injectable ramp-up following a landmark AbbVie licensing deal.
Glenmark Pharmaceuticals launched Lacosamide Injection USP in the United States. This expansion of their injectable portfolio targets a market with $15.2 million in annual sales.
Glenmark delivered strong FY26 growth, hitting gross debt-free status, yet Q4 US margins were squeezed by timing delays and fixed-cost under-absorption.
Glenmark Q4 FY26 consolidated revenue grew 15.8% YoY to ₹37,706m with 20.2% EBITDA margin. Growth driven by landmark AbbVie licensing deal and strong momentum in respiratory franchise.
Glenmark Pharmaceuticals reported FY26 consolidated revenue of ₹16,982.5 Crore, up 27.5% YoY. The company achieved a 26.9% EBITDA margin driven by key product launches and partnerships.
Glenmark Pharmaceuticals recommended a final dividend of ₹2.5 per equity share for FY2026. Shareholder approval at the upcoming general meeting is required for payment.
Glenmark Pharmaceuticals approved transferring its Nebulizer portfolio to its subsidiary for ₹223 Crore. The restructuring aims to enhance strategic focus and respiratory innovation leadership.
Glenmark Pharmaceuticals appointed Ms. Rashmi Khandelwal as Company Secretary following Mr. Harish Kuber's retirement. Ms. Khandelwal brings 17 years of corporate governance experience to the role.